Secondary Logo

November 13, 2018 - Volume 32 - Issue 17
pp: 2439-2649


Interleukin 21 (IL-21)/microRNA-29 (miR-29) axis is associated with natural resistance to HIV-1 infection

Ortega, Paula A.S.; Saulle, Irma; Mercurio, Vincenzo; More

AIDS. 32(17):2453-2461, November 13, 2018.

CONCISE COMMUNICATIONS



HIV-1 second-line failure and drug resistance at high-level and low-level viremia in Western Kenya

Kantor, Rami; DeLong, Allison; Schreier, Leeann; More

AIDS. 32(17):2485-2496, November 13, 2018.

Elvitegravir/cobicistat pharmacokinetics in pregnant and postpartum women with HIV

Momper, Jeremiah D.; Best, Brookie M.; Wang, Jiajia; More

AIDS. 32(17):2507-2516, November 13, 2018.

Women have enhanced bone loss associated with phosphaturia and CD4+ cell restoration during initial antiretroviral therapy

Kalayjian, Robert C.; Albert, Jeffrey M.; Cremers, Serge; More

AIDS. 32(17):2517-2524, November 13, 2018.

Phase I clinical trial of an intranodally administered mRNA-based therapeutic vaccine against HIV-1 infection

Leal, Lorna; Guardo, Alberto C.; Morón-López, Sara; More

AIDS. 32(17):2533-2545, November 13, 2018.


Viremia copy-years and mortality among combination antiretroviral therapy-initiating HIV-positive individuals: how much viral load history is enough?

Wang, Ruibin; Haberlen, Sabina A.; Palella, Frank J. Jr; More

AIDS. 32(17):2547-2556, November 13, 2018.

Neurodevelopmental outcomes and in-utero antiretroviral exposure in HIV-exposed uninfected children

Piske, Micah; Budd, Matthew A.; Qiu, Annie Q.; More

AIDS. 32(17):2583-2592, November 13, 2018.

CD4+ cell count recovery after combined antiretroviral therapy in the modern combined antiretroviral therapy era

Roul, Hélène; Mary-Krause, Murielle; Ghosn, Jade; More

AIDS. 32(17):2605-2614, November 13, 2018.





Show: